GILD - GILEAD SCIENCES, INC.
IEX Last Trade
94.04
0.060 0.064%
Share volume: 62,113
Last Updated: Thu 26 Dec 2024 08:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$93.98
0.06
0.06%
Fundamental analysis
42%
Profitability
48%
Dept financing
24%
Liquidity
19%
Performance
47%
Performance
5 Days
0.59%
1 Month
2.85%
3 Months
13.14%
6 Months
35.55%
1 Year
17.51%
2 Year
10.86%
Key data
Stock price
$94.04
DAY RANGE
$93.11 - $94.25
52 WEEK RANGE
$63.90 - $98.90
52 WEEK CHANGE
$15.79
DIVIDEND
$0.77
EX-DIVIDEND DATE
06/14/2024
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Daniel P. O'Day
Region: US
Website: gilead.com
Employees: 17,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: gilead.com
Employees: 17,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.
Recent news